Extrait

To allow patients who have completed a clinical trial with CPG 7909 Injection or have reached a maximum number of cycles with a combination product (such as chemotherapy) to continue treatment with CPG 7909 if their cancer has responded or stabilised in response to treatment with CPG 7909 Injection alone or in combination with other anti-neoplastic agents.

Critère d'inclusion

• Patients with metastatic or recurrent malignancies who have stable disease or who have responded to CPG 7909 Injection therapy

Liens

• euctr
• ictrp